World Wires · story 18300 · corroborated · 1 source(s)

Drugmakers develop amylin drugs for obesity and diabetes

Eli Lilly and Novo Nordisk are developing new amylin-targeted treatments to complement GLP-1 drugs for obesity and diabetes management.

Open in the desk

Coverage

• Drugmakers develop amylin drugs for obesity and diabetes NewsAPI headlines · tier B · clear net · 2026-10-02 15:13 UTC

What this site indexes